CytoGenix To Move Business From Nevada To Connecticut
The biotech firm is researching an avian flu vaccine
A Nevada-based biotech firm has announced it’s to move to the east coast, and establish a major presence in Connecticut. CytoGenix is researching an avian flu vaccine. WNPR’s Harriet Jones reports.
CytoGenix says it has plans to move its corporate headquarters from the desert Southwest to New York City, as it moves to be listed on the NASDAQ. As part of that relocation, it will also lease space in Middletown.
The Connecticut operation will include both office and lab space, and the company says it hopes to use the facilities to bring its vaccine product forward for FDA approval quickly and efficiently. The avian flu vaccine that it’s developing just this month proved effective in animal trials.
The company hasn’t yet detailed the size of the Middletown operation, or said how many employees it will bring to the site, but it describes the lab facilities as world class. The announcement marks a success for Connecticut in recruiting a new bioscience company, something that’s been a key goal of economic development policies in the state as it seeks to expand high tech industries and skilled employment.
For WNPR, I'm Harriet Jones.